|
- 现金
- 514 元
- 精华
- 0
- 帖子
- 287
- 注册时间
- 2015-10-22
- 最后登录
- 2020-11-7
|
本帖最后由 hbv_challenger 于 2015-12-9 13:08 编辑
一直在听到别人说"古巴新药", 进入其官方网站 http://www.abivax.com 看到以下的资料介绍. 王婆当然说自已的瓜是最好的.
重点是一句话" a pivotal clinical trial in 276 patients ......will deliver top-level results in Q4 of 2016." 所以2016年年底结束关键的3期临床,明年底可以看到最新的结果如何.希望大家保重身体,耐心等待,成功一定在不远的将来.
ABX203, A THERAPEUTIC VACCINE AGAINST CHRONIC HEPATITIS B
ABX203 is a therapeutic vaccine candidate that delivers long-lasting control of the viral load, with a treatment period that is shorter than current standard of care. It is intended for patients with chronic hepatitis B disease. It is composed of both the HBs and HBc antigens and thus a mix of 2 VLP structures.
ABX203 has been tested successfully in 4 clinical trials, including a Phase IIb/III clinical efficacy study in 160 patients with chronic hepatitis B (CHB). In the latter study, ABX203 was compared with peg-Interferon in treatment naïve patients, and was shown to be better tolerated and have a longer viral suppression with half the duration of treatment.
In addition, in December 2014, the candidate therapeutic vaccine entered into a pivotal clinical trial in 276 patients whose viral load had been controlled with NUCs for at least 2 years. This study, conducted in 5 countries in Asia as well as in Australia and New Zealand, completed recruitment in September 2015 and will deliver top-level results in Q4 of 2016.
ABX203 is the first result of the collaboration with Cuban life science excellence. It has been acquired by ABIVAX from the Centre for Genetic Engineering and Biotechnology (CIGB) in Cuba
|
|
发表于 2015-12-9 13:05
